Pharma Capital

Silence Therapeutics continuing to make strong progress on drug pipeline

David Ellam, CFO for Silence Therapeutics PLC (LON:SLN) runs Proactive through the firm's results and highlights for the half year to June 2017.

Ellam says they're continuing to make good progress on their drug pipeline with plans to file their first GalNAc IND application by the end of next year.

He says they're very excited by the state of the industry as a whole.

''It's gone from being a little bit quiet for a little while to this whole new therapeutic modality ... and hopefully there will be a number of drugs available - new drugs for patients, often in areas of high unmet need and that's certainly where we're looking to focus our efforts''.

 

View full SLN profile

Silence Therapeutics plc Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.